SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on the 18th-20th November 2019 in London, UK. The global ophthalmic drug market size is ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Eye drops are the most preferred drug delivery method in the ophthalmic market, yet developing eye drop formulations targeting the retina, located in the posterior segment of the eye, remains a ...

The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore ...

VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...

Glaukos submitted a new drug application to the FDA for Epioxa ... closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA approved, noninvasive ...

The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.